SINTX Technologies acquires SiNAPTIC Surgical assets to enter foot and ankle fusion market
All-equity deal adds six implant systems, a 510(k) pre-submission, and a commercial leadership team as SINTX shifts from R&D to revenue
SINTX Technologies, Inc. (NASDAQ: SINT), a Salt Lake City-based advanced ceramics company, acquired the surgical business assets of SiNAPTIC Holdings, LLC, a privately held silicon nitride ceramic manufacturer, in an all-equity transaction valued at $750,000 in common shares. The deal gives SINTX ownership of six differentiated foot and ankle implant systems, associated intellectual property, and a 510(k) pre-submission intended to accelerate regulatory clearance and near-term commercial launch.
The global ankle fusion market was valued at approximately $750.5 million and is projected to reach $1.38 billion by 2032, representing a compound annual growth rate of 9.1%, according to industry research cited by SINTX.
“This acquisition is transformative for SINTX by adding a family of FDA-reviewed implants, a portfolio of new technologies, and capital, accelerating our shift from R&D to revenue generation and commercial scale,” said Eric Olson, Chief Executive Officer of SINTX Technologies. “The SiNAPTIC team brings deep expertise in product development, regulatory strategy, and commercialization to support our existing commercial product portfolio — key elements in driving increased value for our shareholders.”
The acquired assets include all intellectual property, product designs, and development work related to the six implant systems, each backed by clinical development and mechanical testing. SINTX issued shares priced at $3.465 per share, representing a 10% premium to the company’s closing price on June 20, 2025, along with 325,000 performance-based common stock purchase warrants exercisable over five years at a strike price of $6.30. The warrants vest upon achieving specific regulatory and commercial milestones, including U.S. Food and Drug Administration (FDA) clearance and revenue targets. The common shares are subject to a six-month lock-up agreement.
Several members of SiNAPTIC’s executive team joined SINTX as part of the transaction, taking on roles including Chief Commercial Officer, Senior Vice President of Regulatory and Quality Affairs, and Managing Director of Business Development. Dr. Bryan Scheer, who served as Chairman and CEO of SiNAPTIC, will chair a newly formed Clinical Advisory Board at SINTX to guide product development and surgeon engagement.
“This acquisition reflects our shared belief in the transformative potential of silicon nitride ceramic-enhanced implants and the strength of our combined teams,” Dr. Scheer said. “Together, we can accelerate the development of disruptive products and deliver meaningful clinical value.”
SINTX plans to manufacture all acquired devices under its FDA-registered and ISO-certified quality system, leveraging existing FDA clearances and Master Files to streamline the regulatory approval process for the new implant portfolio.
